Eyecare Innovations Today: An Ophthalmic Educational Podcast Series

Unveiling the Paradox: BAK's Role in American Pharmaceuticals With Dr. Nate Radcliffe

11 min · 5. juni 2024
episode Unveiling the Paradox: BAK's Role in American Pharmaceuticals With Dr. Nate Radcliffe cover

Description

In this episode, Nathan Radcliffe, MD, discusses the widespread use of benzalkonium chloride (BAK) in the US ophthalmic market. Dr. Radcliffe acknowledges concerns about its long-term effects, such as exacerbating dry eye and impacting the success of incisional glaucoma surgery. Preservative-free formulations are favored in Europe, and Dr. Radcliffe highlights the growing recognition among US eye care clinicians regarding the need for BAK alternatives. This activity is supported by an independent medical education grant from Théa Pharma.

Comments

0

Be the first to comment

Sign up now and become a member of the Eyecare Innovations Today: An Ophthalmic Educational Podcast Series community!

Get Started

1 month for 9 kr.

Then 99 kr. / month · Cancel anytime.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

All episodes

65 episodes

episode The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer artwork

The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer

In this episode, Anton Hommer, MD, discusses the European perspective on adopting preservative-free pharmaceuticals, highlighting challenges like health care professionals’ reluctancy to change, diverse reimbursement systems, and higher costs. He compares single-use and multiuse drugs, considering factors such as environmental impact and cost-effectiveness. Dr. Hommer emphasizes the superior efficacy of preservative-free medications, especially in treating chronic conditions such as glaucoma, and anticipates an increase in their use to protect ocular health and enhance chronic disease management. This activity is supported by an independent medical education grant from Théa Pharma.

4. juni 202411 min